IMpower 132: Loses Power at the Finish Line

Affiliations

¹ Department of Medicine Division of Medical Oncology, University of California San Diego, San Diego, California.
² Department of Medicine Division of Hematology Oncology, University of California Davis, Davis, California. Electronic address: karkelly@UCDAVIS.edu.

Free article

Editorial

Sandip Pravin Patel et al. J Thorac Oncol. 2021 Apr.

Free article

. 2021 Apr;16(4):512-514.

doi: 10.1016/j.jtho.2021.02.007.

¹ Department of Medicine Division of Medical Oncology, University of California San Diego, San Diego, California.
² Department of Medicine Division of Hematology Oncology, University of California Davis, Davis, California. Electronic address: karkelly@UCDAVIS.edu.

No abstract available

Comment on

Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial.
Nishio M, Barlesi F, West H, Ball S, Bordoni R, Cobo M, Longeras PD, Goldschmidt J Jr, Novello S, Orlandi F, Sanborn RE, Szalai Z, Ursol G, Mendus D, Wang L, Wen X, McCleland M, Hoang T, Phan S, Socinski MA. Nishio M, et al. J Thorac Oncol. 2021 Apr;16(4):653-664. doi: 10.1016/j.jtho.2020.11.025. Epub 2020 Dec 14. J Thorac Oncol. 2021. PMID: 33333328 Clinical Trial.